VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Mesa Laboratories Executive Compensation (FY26)

MLAB · Executive and director compensation, fiscal 2022 to 2026
Latest say-on-pay support
=
September 8, 2026
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Mesa Laboratories brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): September 8, 2026
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Mesa Laboratories brief$500Get the executive brief
Velarion Intel, one year, every company
245 figures on this page: 233 cited to the filing that reported them, 12 calculated from figures it prints. See the citations
What changed from fiscal 2025 to fiscal 2026
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Gary Owens: $6,599,891 → $6,643,208 (0.7% higher)

Frequently asked questions

Answers drawn from the data on this page.
What was Mesa Laboratories' say-on-pay result?
For fiscal 2026, shareholders backed the say-on-pay proposal with 96.9% of votes cast for or against in favor at the meeting held September 8, 2026.
Which companies are in Mesa Laboratories' peer group?
Companies named in the disclosed peer group include Adaptive Biotechnologies Corporation, Artivion, Inc., AtriCure, Inc., Azenta, Inc. and BioLife Solutions, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gary Owens
CEO and President
◇—◇◇◇—◇— not reconciled
John Sakys
Chief Financial Officer
◇—◇◇◇—◇◇
Greg DiNoia
SVP Commercial
◇—◇◇◇—◇◇
Brian Archbold
SVP of Operations and Continuous Improvement
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gary Owens
CEO and President
◇—◇◇◇—◇◇
John Sakys
VP and Chief Financial Officer
◇—◇◇◇—◇◇
Brian Archbold
SVP of Operations and Continuous Improvement
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gary Owens
Former CEO and President
◇—◇◇◇—◇◇
John Sakys
VP and Chief Financial Officer
◇—◇◇◇—◇◇
Brian Archbold
SVP of Operations and Continuous Improvement
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gary Owens
Former CEO and President
◇—◇—◇—◇◇
John Sakys
VP and Chief Financial Officer
◇—◇—◇—◇◇
Brian Archbold
SVP of Operations and Continuous Improvement
◇—◇—◇—◇◇
Fiscal 2026
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gary Owens
Former CEO and President
Departed during or after this year
◇—◇—◇—◇◇
John Sakys
VP and Chief Financial Officer
◇—◇—◇—◇◇
Brian Archbold
SVP of Operations and Continuous Improvement
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2026
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brian ArchboldRSU◇——◇——◇
Brian ArchboldPSU◇◇◇—◇—◇
Gary OwensPSU◇◇◇—◇—◇
Gary OwensRSU◇——◇——◇
John SakysPSU◇◇◇—◇—◇
John SakysRSU◇——◇——◇
Fiscal 2022, 2025 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2026 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Gary OwensPSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇6/21/2029
RSU◇◇——
John SakysRSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇6/21/2029
RSU◇◇——
Brian ArchboldPSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇6/21/2029
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Brian Archbold
SVP of Operations and Continuous Improvement · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
John Sakys
VP and Chief Financial Officer
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2026
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Sullivan
Board chair
◇◇————◇
Jennifer Alltoft
◇◇————◇
Tony Tripeny
◇◇————◇
Mark Capone
◇◇————◇
Shiraz Ladiwala
Lead independent director
—◇————◇
Shannon Hall
◇◇————◇
Siddhartha Kadia served on the board in fiscal 2026 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇
Equity is delivered as restricted stock units.
Stock ownership guideline: 3x annual retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2026
  • Adaptive Biotechnologies Corporation ADPT
  • Artivion, Inc. AORT
  • AtriCure, Inc. ATRC
  • Azenta, Inc. AZTA
  • BioLife Solutions, Inc. BLFS
  • Codexis, Inc. CDXS
  • Cryoport, Inc. CYRX
  • Cytek Biosciences, Inc. CTKB
  • Haemonetics Corporation HAE
  • Inogen, Inc. INGN
  • LeMaitre Vascular, Inc. LMAT
  • Maravai LifeSciences Holdings, Inc. MRVI
  • Neogen Corporation NEOG
  • Neogenomics, Inc. NEO
  • Pacific Biosciences of California, Inc. PACB
  • Quanterix Corporation QTRX
  • Sotera Health, LLC SHC
  • Standard BioTools, Inc. LAB
  • Veracyte, Inc. VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2026September 8, 2026=◇◇◇
2025August 22, 2025=◇◇◇
2024August 30, 2024=◇◇◇
2023August 30, 2024=◇◇◇
2022August 25, 2023=◇◇◇
2021August 26, 2022=◇◇◇
2020August 27, 2021=◇◇◇
2019August 28, 2020=◇◇◇
2018November 5, 2019=◇◇◇
2017October 30, 2018=◇◇◇
2016November 2, 2017=◇◇◇
2015November 2, 2016=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Gary Owens (Former CEO and President), FY2026 total compensation $6,643,208 (base salary $808,846) [exec_comp, SEC accession 0000724004-26-000071, filed 2026-07-22]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Mesa Laboratories files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Mesa Laboratories disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Mesa Laboratories sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Mesa Laboratories' disclosed peer group is defensible, who names Mesa Laboratories back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
245 figures on this page: 233 cited to the filing that reported them, 12 calculated from figures it prints.
233 cited to the filing
12 calculated from the filing

Documents cited

  1. 0001437749-26-029813
    ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
  2. 0000724004-26-000071
    Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at March 31, 2026 · Summary Compensation Table
  3. 0001437749-25-027659
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001437749-25-022559
    Compensation Discussion and Analysis · Summary Compensation Table
  5. 0001437749-24-028148
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001437749-24-023040
    Summary Compensation Table
  7. 0001437749-23-024684
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001437749-22-021400
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001437749-22-017099
  10. 0001437749-21-021073
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001437749-20-018946
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001437749-19-021573
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001437749-18-019035
  14. 0001437749-17-018125
  15. 0001437749-16-040822
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Mesa Laboratories executive compensation, FY2022–FY2026.” https://intel.velarion.ai/comp/MLAB (accessed 2026).
Short form: data: Velarion

The Mesa Laboratories brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Mesa Laboratories and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Mesa Laboratories discloses

The companies named in MLAB's own disclosed peer group.

Adaptive Biotechnologies CorporationArtivion, Inc.AtriCure, Inc.Azenta, Inc.BioLife Solutions, Inc.Codexis, Inc.Cryoport, Inc.Cytek Biosciences, Inc.Haemonetics CorporationInogen, Inc.LeMaitre Vascular, Inc.Maravai LifeSciences Holdings, Inc.Neogen CorporationNeogenomics, Inc.Pacific Biosciences of California, Inc.Quanterix CorporationSotera Health, LLCStandard BioTools, Inc.Veracyte, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy